Free Trial
OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Price, News & Analysis

Arch Therapeutics logo

About Arch Therapeutics Stock (OTCMKTS:ARTH)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.16
$0.26
52-Week Range
N/A
Volume
2,500 shs
Average Volume
4,068 shs
Market Capitalization
$763,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Arch Therapeutics, Inc. (ARTH)
Arch Therapeutics Inc ARTH
See More Headlines

ARTH Stock Analysis - Frequently Asked Questions

Arch Therapeutics, Inc. (OTCMKTS:ARTH) issued its earnings results on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01.

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), Adobe (ADBE), GE Aerospace (GE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
7/23/2020
Today
5/11/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,980,000.00
Net Margins
-8,257.70%
Pretax Margin
-8,257.70%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Price / Cash Flow
N/A
Book Value
($2.43) per share
Price / Book
N/A

Miscellaneous

Free Float
4,529,000
Market Cap
$763,000.00
Optionable
Not Optionable
Beta
4.02

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (OTCMKTS:ARTH) was last updated on 5/11/2025 by MarketBeat.com Staff
From Our Partners